ENSC
What one share of Ensysce Biosciences holds
Pharmaceutical Preparations
Ensysce Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.68 |
|---|---|
| Profit | −$1.90 |
| Cash and investments | $0.04 |
| Debt | $0.01 |
| Book value | −$0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$63.00 | — | −$56.31 | — | $248.38 |
| 2021 | $52.54 | −$444.64 | — | −$122.62 | — | −$95.91 |
| 2022 | $210.37 | −$2,091 | — | −$1,491 | — | — |
| 2023 | $14.78 | −$70.40 | — | −$71.42 | — | −$1.54 |
| 2024 | $7.47 | −$11.45 | — | −$10.75 | — | $2.74 |
| 2025 | $1.98 | −$3.98 | $0.05 | −$3.10 | — | $0.70 |